Announced Mon, 10 Aug · 15:53 IST
Shilpa Medicare Q1FY27 - record revenue INR469cr, EBITDA INR139cr
Order Pipeline DisclosedMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹808.00
prior close
₹809.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.4-0.0+0.3-0.6+0.1+1.9+0.1+0.4+1.6————
Up moveDown movePending
AI summary
Shilpa Medicare posted highest-ever quarterly revenue of INR469 crores, up 43% year-on-year, with EBITDA of INR139 crores at 30% margin and PAT of INR101 crores, up 115% YoY. API grew 15%, Formulation over 100%, and Biologics 42%. Net debt-to-EBITDA fell to 1.3x from 6.7x, ROCE rose to 12.5%, and credit rating was upgraded to AA-. Multiple biosimilar, CDMO, and complex formulation launches planned through FY28. Q1 capex was INR114 crores.
Likely market impact
Record quarter with broad-based growth, improved return ratios, and credit rating upgrade. Pipeline of complex product launches through FY28 supports growth.